108 related articles for article (PubMed ID: 26118713)
1. Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer.
Yuan J; Kang JL; Liao H; Wang XX; Nie ML; Shuai R; Deng C
Anticancer Agents Med Chem; 2015; 15(10):1308-16. PubMed ID: 26118713
[TBL] [Abstract][Full Text] [Related]
2. MAP2K6-FP Enhances the Sensitiveness of Paclitaxel for Ovarian Cancer via Inducing Autophagy.
Guo Y; Yuan J; Yin S; Wang X; Shuai R; Kang J
Int J Gynecol Cancer; 2017 Jul; 27(6):1082-1087. PubMed ID: 28604448
[TBL] [Abstract][Full Text] [Related]
3. TAT-OSBP-1-MKK6(E), a novel TAT-fusion protein with high selectivity for human ovarian cancer, exhibits anti-tumor activity.
Zhong J; Kang J; Wang X; Jiang W; Liao H; Yuan J
Med Oncol; 2015 Apr; 32(4):118. PubMed ID: 25782870
[TBL] [Abstract][Full Text] [Related]
4. Delivery of Constitutively Active Mutant MKK6(E) With TAT-OSBP Induces Apoptosis in Human Ovarian Carcinoma HO8910 Cells.
Liao H; Kang JL; Jiang WY; Deng C; Yuan J; Shuai R
Int J Gynecol Cancer; 2015 Nov; 25(9):1548-56. PubMed ID: 26495757
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
[TBL] [Abstract][Full Text] [Related]
6. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Anticancer Activity of Combined Use of Caffeic Acid with Paclitaxel Enhances Apoptosis of Non-Small-Cell Lung Cancer H1299 Cells in Vivo and in Vitro.
Min J; Shen H; Xi W; Wang Q; Yin L; Zhang Y; Yu Y; Yang Q; Wang ZN
Cell Physiol Biochem; 2018; 48(4):1433-1442. PubMed ID: 30064123
[TBL] [Abstract][Full Text] [Related]
8. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
[TBL] [Abstract][Full Text] [Related]
9. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
10. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
11. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
12. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
14. The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer.
Zhao H; Li R; Wang X; Lu X; Hu M; Zhang J; Zhao X; Song X; Liu Y
J Ovarian Res; 2020 Sep; 13(1):113. PubMed ID: 32958014
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
[TBL] [Abstract][Full Text] [Related]
16. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.
Sui M; Chen F; Chen Z; Fan W
Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381
[TBL] [Abstract][Full Text] [Related]
20. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
Tedjarati S; Baker CH; Apte S; Huang S; Wolf JK; Killion JJ; Fidler IJ
Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
